News Zai Lab Limited

Stocks

ZLAB

US98887Q1040

Pharmaceuticals

Market Closed - Nasdaq 08:00:00 03/11/26 am AEDT			5-day change	1st Jan Change
21.66 ^USD	-1.84%		-10.99%	+22.82%

28/10	Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading	MT
26/10	Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4%	MT

All News

Mentions Relevance

26/10	Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4%	MT
24/10	Zai Lab Limited - Special Call
23/10	Zai Lab Says Zoci Plus Atezolizumab Improves Response Rate in Phase 1 Lung Cancer Trial	MT
23/10	Zai Lab Limited Shares First Data From Global Phase 1b Clinical Trial Evaluating Zocilurtatug Pelitecan In Combination With Atezolizumab With And Without Carboplatin As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer	CI
23/10	Zai Lab’s Zocilurtatug Pelitecan (Zoci, Formerly ZL-1310) Demonstrates High Response Rates, Encouraging Durability and Well-Tolerated Safety Profile in First-Line Extensive-Stage Small Cell Lung Cancer	BU
23/10	Zai Lab to Privately Place $250 Million in ADRs to Fund Drug Research	MT
23/10	Zai Lab to Raise $250 Million in Private Placement of ADSs	MT
23/10	Zai Lab Announces $250 Million Private Placement	BU
22/10	Zai Lab Limited announced that it expects to receive $249.9336 million in funding	CI
21/10	Zai Lab to Announce Third Quarter 2026 Financial Results and Recent Corporate Updates on November 5, 2026	BU
14/10	Zai Lab Limited to Present Data from First Clinical Trial Evaluating ZL 1503, an Il-13/Il-31Ra Bispecific Antibody, for Atopic Diseases	CI
14/10	Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases	BU
30/09	Zai Lab Limited To Present First Global Data From Clinical Trial Evaluating Zocilurtatug Pelitecan As First-Line Treatment For Extensive-Stage Small Cell Lung Cancer	CI
29/09	Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)	BU
26/08	Zai Lab's Net Loss Widens 14% in H1, Revenue Drops 6%	MT
17/08	Zai Lab and argenx Announce Positive Topline Results from Phase 3 ALKIVIA Trial of Efgartigimod in Autoimmune Myositis	BU
17/08	Zai Lab Limited and Argenx Announces Positive Topline Results From Phase 3 Alkivia Trial Of Efgartigimod In Autoimmune Myositis	CI
07/08	Zai Lab Limited, Q2 2026 Earnings Call, Aug 06, 2026
07/08	Zai Lab Shares Rise After Q2 Beat	MT
06/08	Zai Lab Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
06/08	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Revenue $106.3M, vs. FactSet Est of $103.9M	MT
06/08	Earnings Flash (ZLAB) Zai Lab Limited Reports Q2 Loss of $0.46 per ADS, vs. FactSet Est of $-0.68	MT
06/08	Zai Lab Announces Second Quarter 2026 Financial Results and Recent Corporate Updates	BU
03/08	Zai Lab Receives FDA Orphan Drug Designation for Zocilurtatug Pelitecan in Neuroendocrine Carcinomas	MT
03/08	U.S. FDA Grants Orphan Drug Designation to Zai Lab’s DLL3-Targeting ADC Zocilurtatug Pelitecan (Zoci) for the Treatment of Neuroendocrine Carcinomas (NECs)	BU